What is Castleman disease?
Castleman disease is a rare disorder of the lymph nodes. It is not one disease but a group of related conditions that share the same changes in lymph node tissue under the microscope. It is named after Dr Benjamin Castleman, who first described it in the 1950s.
In Castleman disease, lymph nodes become enlarged because of an overgrowth of immune cells and blood vessels. In some forms, the immune system also releases large amounts of inflammatory signalling proteins, especially interleukin-6 (IL-6). This can make people very unwell, with fever, fluid build-up and organ damage.
Castleman disease is not a cancer, but it is treated by blood cancer (haematology) specialists, and some treatments are similar to those used for lymphoma. It is also linked with a higher risk of lymphoma and some other conditions (Dispenzieri and Fajgenbaum, 2020).
There are two main types:
- Unicentric Castleman disease (UCD) affects one lymph node or one group of nodes. It usually causes few symptoms and is often cured by surgery.
- Multicentric Castleman disease (MCD) affects several groups of lymph nodes around the body. It causes whole-body inflammation and needs medicines to control it.
Multicentric disease is further divided by its cause. Some cases are caused by the virus HHV-8, mainly in people with HIV. Others have no known cause and are called idiopathic multicentric Castleman disease (iMCD).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of condition | Rare lymph node disorder (lymphoproliferative disorder) |
| Is it cancer? | No, but it is treated by haematologists and can be serious |
| Main types | Unicentric (UCD) and multicentric (MCD) |
| Typical age | UCD: often 30s-40s; iMCD: often 40s-50s; can occur at any age |
| Common sites | Chest, neck, abdomen, armpits and groin |
| Key protein | Interleukin-6 (IL-6), especially in multicentric forms |
| Main treatments | Surgery for UCD; siltuximab or other medicines for iMCD; rituximab for HHV-8 MCD |
| Outlook | Excellent for UCD; variable for multicentric forms |
2. Causes and types
The causes of Castleman disease differ between types.
| Type | Cause | Who is affected |
|---|---|---|
| Unicentric (UCD) | Probably a clonal growth of supporting (stromal) cells in one lymph node region | Young and middle-aged adults; children too |
| HHV-8-associated MCD | Infection with human herpesvirus 8 (Kaposi sarcoma herpesvirus) | Mostly people with HIV; also some people in areas where HHV-8 is common |
| Idiopathic MCD (iMCD) | Unknown; thought to involve an overactive immune system | Adults of any age, most often 40s-50s |
| iMCD-TAFRO | A severe form of iMCD with sudden onset | Adults; first described in Japan |
| POEMS-associated MCD | Occurs with POEMS syndrome, a plasma cell disorder | Adults with POEMS syndrome |
The role of interleukin-6
IL-6 is a messenger protein that helps control inflammation. In multicentric Castleman disease, too much IL-6 (or, in HHV-8 MCD, a viral form of IL-6) drives many of the symptoms:
- Fever and night sweats
- Anaemia and low albumin
- Fluid build-up in the body
- Enlarged liver and spleen
- High CRP and other markers of inflammation
This is why medicines that block IL-6 are the first choice for iMCD (van Rhee et al., 2018).
Conditions linked with Castleman disease
| Linked condition | Notes |
|---|---|
| Kaposi sarcoma | In HHV-8-associated disease |
| Lymphoma | Higher risk, especially in HHV-8 MCD |
| POEMS syndrome | Often occurs with a Castleman-like lymph node picture |
| Paraneoplastic pemphigus | A severe blistering disease, mainly with UCD |
| Follicular dendritic cell sarcoma | Can rarely arise in UCD |
3. How does it look
On the body and on scans
| Feature | UCD | MCD |
|---|---|---|
| Lymph nodes | One enlarged node or a cluster in one area, often several centimetres | Many moderately enlarged nodes in different areas |
| Common sites | Chest (mediastinum), neck, abdomen, pelvis | Neck, armpits, groin, chest and abdomen together |
| Liver and spleen | Normal | Often enlarged |
| Fluid | None | Fluid in the abdomen, around the lungs or under the skin, especially in TAFRO |
| PET-CT | Mild to moderate tracer uptake | Usually mild to moderate uptake in many nodes |
Under the microscope
Pathologists describe several patterns.
| Pattern | Features | Most common in |
|---|---|---|
| Hyaline vascular (hypervascular) | Shrunken germinal centres, “onion-skin” layers of small lymphocytes, and blood vessels running into the centres (“lollipop” appearance) | UCD |
| Plasmacytic | Sheets of plasma cells between the follicles | iMCD and HHV-8 MCD |
| Mixed | Features of both | iMCD |
| HHV-8-positive | Plasmablasts that stain for the HHV-8 protein LANA-1 | HHV-8 MCD |
These changes are not unique to Castleman disease. Similar patterns can be seen in infections, autoimmune diseases and lymphoma, so doctors must rule these out (Fajgenbaum et al., 2017).
4. Symptoms
Unicentric Castleman disease
Many people have no symptoms, and the enlarged node is found by chance on a scan. Others notice:
- A painless lump in the neck, armpit or groin
- Cough, chest pain or breathlessness if the mass is in the chest
- Tummy discomfort or fullness if it is in the abdomen
- Mouth sores and blisters in the rare case of paraneoplastic pemphigus
Multicentric Castleman disease
Symptoms can range from mild to life-threatening:
- Fever and drenching night sweats
- Tiredness and weakness
- Weight loss and loss of appetite
- Swollen lymph nodes in several areas
- Swelling of the legs or the whole body (oedema)
- Swollen tummy from fluid or an enlarged liver and spleen
- Shortness of breath from fluid around the lungs
- Skin changes, such as small red-purple spots (cherry haemangiomas)
- Numbness or tingling in the hands and feet
iMCD-TAFRO
The TAFRO form is named after its main features (Nishimura et al., 2021):
| Letter | Feature |
|---|---|
| T | Thrombocytopenia (low platelets) |
| A | Anasarca (severe fluid build-up throughout the body) |
| F | Fever |
| R | Reticulin fibrosis of the bone marrow and renal (kidney) failure |
| O | Organomegaly (enlarged liver, spleen and lymph nodes) |
TAFRO can develop over days to weeks and often needs hospital treatment.
When to seek medical advice
See a doctor about lumps that persist for more than 2-3 weeks, or about fever, night sweats and weight loss. Seek urgent help for rapidly increasing swelling, breathlessness or reduced urine output.
5. Diagnosis
| Test | Purpose |
|---|---|
| Lymph node biopsy | Essential; the whole node or a large sample is best |
| Blood count | Anaemia, high or low platelets |
| CRP and ESR | Measure inflammation |
| Albumin, kidney and liver tests | Check for organ involvement |
| Immunoglobulins | Often raised in multicentric disease |
| HIV and HHV-8 tests | Separate HHV-8 MCD from iMCD |
| Tests for autoimmune disease and infection | Rule out other causes |
| PET-CT or CT | Show how many lymph node areas are involved |
| Bone marrow biopsy | Often in iMCD-TAFRO and when lymphoma is suspected |
Diagnostic criteria for iMCD
International criteria require all three of the following (Fajgenbaum et al., 2017):
| Part | Requirement |
|---|---|
| Major criteria | Typical lymph node changes on biopsy, and enlarged lymph nodes (1 cm or more) in at least 2 areas |
| Minor criteria | At least 2 of 11 clinical and laboratory features, including at least 1 laboratory feature, such as high CRP, anaemia, low albumin or kidney problems |
| Exclusion | Infections (including HHV-8), autoimmune diseases and cancers that can look similar must be ruled out |
6. Treatment
Unicentric Castleman disease
| Treatment | Notes |
|---|---|
| Surgery | Complete removal of the affected node or nodes cures most people |
| Watch and wait | For small, symptom-free masses that cannot easily be removed |
| Radiotherapy, embolisation or medicines | For masses that cannot be removed; may shrink them before surgery |
International guidelines recommend complete surgical removal whenever it is safe (van Rhee et al., 2020).
Idiopathic multicentric Castleman disease
| Treatment | Notes |
|---|---|
| Siltuximab | An antibody that blocks IL-6; the recommended first treatment |
| Tocilizumab | Blocks the IL-6 receptor; used where siltuximab is unavailable |
| Corticosteroids | Often added for severe symptoms, then reduced |
| Rituximab | For milder disease or when IL-6 blockade does not work |
| Sirolimus | An mTOR inhibitor; helps some people who do not respond to IL-6 blockade |
| Combination chemotherapy | For severe or life-threatening disease that does not respond to other treatment |
In a randomised trial, siltuximab controlled the disease in about a third of people, compared with none on placebo (van Rhee et al., 2014). It is approved in the US and Europe for iMCD.
HHV-8-associated MCD
| Treatment | Notes |
|---|---|
| Rituximab | The main treatment; often very effective |
| Etoposide or liposomal doxorubicin | Added for severe disease or Kaposi sarcoma |
| Antiretroviral therapy | For people with HIV; essential to control the virus |
| Antiviral drugs | Sometimes used against HHV-8 |
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, bleeding, effects depending on the site |
| Siltuximab or tocilizumab | Infections, rash, itching, weight gain, raised cholesterol, low blood counts |
| Rituximab | Infusion reactions, infections, rarely reactivation of hepatitis B |
| Corticosteroids | Raised blood sugar, mood changes, weight gain, bone thinning |
| Chemotherapy | Low blood counts, infections, nausea, hair loss |
What treatment involves day to day
| Part of treatment | What to expect |
|---|---|
| Siltuximab | A drip lasting about 1 hour every 3 weeks, usually continued long term |
| Blood tests | Before each infusion to check blood counts and response |
| Surgery for UCD | Often keyhole surgery; hospital stay of a few days |
| Hospital care for TAFRO | Intensive treatment, sometimes in high-dependency care, until the illness is controlled |
Castleman disease in children
Castleman disease is uncommon in children. When it does occur, it is usually unicentric and is most often found in the neck, chest or abdomen. Surgery is usually curative.
Multicentric disease in children is rare. It is treated in a similar way to adults, with care from a paediatric haematology team.
7. Outlook (prognosis)
| Type | Outlook |
|---|---|
| UCD | Excellent; most people are cured by surgery and survival is close to normal |
| iMCD | Variable; many people do well on long-term treatment, but some have severe disease |
| iMCD-TAFRO | Can be life-threatening without prompt treatment; many recover with intensive care |
| HHV-8 MCD | Much improved since rituximab and effective HIV treatment |
In older studies, about two-thirds to three-quarters of people with multicentric disease were alive 5 years after diagnosis. Outcomes are now improving with IL-6 blockade and better recognition of the disease (Dispenzieri and Fajgenbaum, 2020).
Factors linked with a poorer outlook in multicentric disease
- The TAFRO form, especially with kidney failure or severe fluid build-up
- Low platelets and low albumin
- Older age and other serious illnesses
- No response to first treatment
- Development of lymphoma or Kaposi sarcoma
8. Follow-up
| Follow-up | Purpose |
|---|---|
| Clinic review | Every few months at first, then less often for UCD |
| Blood tests | CRP, blood count, albumin and kidney function to track activity |
| Scans | CT or PET-CT to check node size and response |
| Lymphoma watch | New or fast-growing nodes may need another biopsy |
9. Living with Castleman disease
- Keep infusion appointments; stopping IL-6 blockade can cause relapse
- Report fever early, as infections can be more serious on treatment
- Stay up to date with vaccinations, avoiding live vaccines while on treatment unless advised
- Track your symptoms, such as fevers, sweats and swelling
- Bring a list of your medicines to every appointment, as some interact with IL-6 blockers
- Rest when you need to; fatigue is common, especially during flares
- Connect with patient networks, such as the Castleman Disease Collaborative Network
- Consider registry and research participation; it helps improve care for a rare disease
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is Castleman disease cancer? | No, but it is treated by haematologists and can be serious |
| Is it contagious? | No. HHV-8 is a virus, but Castleman disease itself is not passed on by contact |
| Is it inherited? | No |
| Will I need treatment forever? | UCD is usually cured by surgery; iMCD often needs long-term treatment |
| Can it turn into lymphoma? | The risk of lymphoma is higher than average, especially in HHV-8 MCD |
| Why did the diagnosis take so long? | It is rare and its symptoms overlap with infections, autoimmune diseases and lymphoma |
| Can UCD come back after surgery? | Rarely, if the whole mass was removed |
| Can I live a normal life with iMCD? | Many people lead full lives while on long-term treatment, with regular check-ups |
| Can I get pregnant while on treatment? | Discuss this with your team first; some treatments need to be paused or changed |
11. Questions to ask your care team
- Do I have unicentric or multicentric disease?
- Has HHV-8 been tested?
- Can the affected node be removed surgically?
- Is siltuximab available to me?
- How will we know if the treatment is working?
- What symptoms should make me contact the team urgently?
Resources
- Dispenzieri, A. and Fajgenbaum, D.C. (2020) ‘Overview of Castleman disease’, Blood, 135(16), pp. 1353-1364.
- Fajgenbaum, D.C. et al. (2017) ‘International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease’, Blood, 129(12), pp. 1646-1657.
- Nishimura, Y. et al. (2021) ‘Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castleman disease’, American Journal of Hematology, 96(10), pp. 1241-1252.
- van Rhee, F. et al. (2014) ‘Siltuximab for multicentric Castleman’s disease: a randomised, double-blind, placebo-controlled trial’, Lancet Oncology, 15(9), pp. 966-974.
- van Rhee, F. et al. (2018) ‘International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease’, Blood, 132(20), pp. 2115-2124.
- van Rhee, F. et al. (2020) ‘International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease’, Blood Advances, 4(23), pp. 6039-6050.
- National Cancer Institute (2026) Drugs Approved for Multicentric Castleman Disease. Available at: https://www.cancer.gov/about-cancer/treatment/drugs/multicentric-castleman-disease (Accessed: October 2026).
Prepared by the editorial team, October 2026.